Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$33.97

-0.055 (-0.16%)

12:37
05/19/17
05/19
12:37
05/19/17
12:37

AstraZeneca announces positive CHMP opinion for brodalumab

AstraZeneca announced that its partner LEO Pharma has received a positive opinion from the Committee for Medicinal Products for Human Us eof the European Medicines Agency recommending the approval of brodalumab for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Brodalumab is the first and only fully human monoclonal antibody that selectively targets the IL-17 receptor. By binding to the receptor, brodalumab effectively blocks the biological activity of several pro-inflammatory IL-17 cytokines, which are important in psoriasis, a chronic, debilitating skin disease that causes red patches of skin covered with silvery scales. In July 2016, AstraZeneca announced an agreement granting LEO Pharma exclusive rights to develop and commercialise brodalumab in Europe. The announcement follows the approval of brodalumab by the US Food and Drug Administration in February 2017 and the approval by the Japanese Pharmaceuticals and Medical Devices Agency in 2016. The CHMP's positive opinion on brodalumab will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union.The final decision is applicable to all EU and European Economic Area countries. Reference Link

  • 19

    May

  • 26

    Jun

AZN AstraZeneca
$33.97

-0.055 (-0.16%)

05/12/17
05/12/17
UPGRADE

Neutral
AstraZeneca upgraded to Neutral at Credit Suisse
As previously reported, Credit Suisse analyst Rebekah Harper upgraded AstraZeneca to Neutral from Underperform after the company reported surprise positive headline results from the Phase 3 PACIFIC trial for Imfinzi in stage 3 unresectable lung cancer in all-comers, with positive progression free survival data. The analyst believes that AstraZeneca is in a "unique position" with this indication, with a likely two to three years lead versus competitors, as other P3s are not due until 2020+. Harper expects U.S. approval for AstraZeneca in this indication before the end of 2017.
05/15/17
LEER
05/15/17
NO CHANGE
LEER
GlaxoSmithKline possible move to buyout Novartis stake makes sense, says Leerink
Leerink analyst Seamus Fernandez is not surprised by the news that GlaxoSmithKline (GSK) may buyout Novartis' (NVS) 36.5% stake in its Consumer Healthcare joint venture through a GBP8B deal sooner rather than later. The analyst believes this buyout could be beneficial as the infusion of additional cash from the buyout could bolster Novartis appetite for large scale M&A, including companies such as AstraZeneca (AZN) whose immune-oncology assets could complement its small-molecule focused oncology portfolio, according to the London Times.
05/16/17
LEER
05/16/17
NO CHANGE
Target $36
LEER
Outperform
AstraZeneca price target raised to $36 from $33 at Leerink
Leerink analyst Seamus Fernandez raised his price target for AstraZeneca to $36 after hosting a call with a lung cancer specialist. The specialist believes that once approved, the uptake of AstraZeneca's Imfinzi in Stage III unresectable non-small cell lung cancer will be "significant" given the poor outcomes and general lack of an effective treatment standard in this setting, Fernandez tells investors in a research note. The analyst raised his peak worldwide forecasts for the drug by $1B and keeps an Outperform rating on AstraZeneca.
05/17/17
JPMS
05/17/17
UPGRADE
Target $72
JPMS
Overweight
Clovis upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Cory Kasimov upgraded Clovis Oncology (CLVS) to Overweight and raised his price target for the shares to $72 from $58. The stock closed yesterday up 2%, or $1.05, to $49.56. The shares are down 35% over the last two months for "no clear fundamental reason," Kasimov tells investors in a research note. The analyst is "increasingly comfortable" recommending Clovis ahead of its Phase 3 study evaluating Rubraca in maintenance ovarian cancer now that more PARP class data has emerged. He has not seen "convincing evidence" that there is a clear efficacy difference between Clovis' rucaparib, Tesaro's (TSRO) niraparib and AstraZeneca's (AZN) olaparib.

TODAY'S FREE FLY STORIES

11:50
10/20/17
10/20
11:50
10/20/17
11:50
General news
NY Fed GDP forecasts trimmed: »

NY Fed GDP forecasts…

CTL

CenturyLink

$18.82

0.33 (1.78%)

11:40
10/20/17
10/20
11:40
10/20/17
11:40
Options
Serious call buying in CenturyLink »

Serious call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$174.56

-1.47 (-0.84%)

11:39
10/20/17
10/20
11:39
10/20/17
11:39
Periodicals
New Facebook feature Sets to rival Pinterest, TechCrunch reports »

A new Facebook feature…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 01

    Nov

  • 08

    Nov

  • 15

    Nov

SHW

Sherwin-Williams

$388.13

0.5634 (0.15%)

11:33
10/20/17
10/20
11:33
10/20/17
11:33
Periodicals
Clearfield's Hilal pitches Sherwin-Williams as long idea, Bloomberg says »

Clearfield Capital's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 30

    Oct

THFF

First Financial

$48.00

-0.05 (-0.10%)

11:30
10/20/17
10/20
11:30
10/20/17
11:30
Hot Stocks
First Financial declares special dividend of $1.50 per share »

The directors of First…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLT

iShares 20+ Year Treasury Bond Fund

$125.31

0.22 (0.18%)

11:30
10/20/17
10/20
11:30
10/20/17
11:30
Options
iShares Longer-term Bond ETF with notable put activity as shares fall »

iShares Longer-term Bond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$15.36

0.11 (0.72%)

11:21
10/20/17
10/20
11:21
10/20/17
11:21
Periodicals
Snap makes more employee cuts, plans to slow hiring in 2018, BI reports »

Snap has laid off 18…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 07

    Nov

  • 08

    Nov

  • 15

    Nov

S

Sprint

$7.00

-0.075 (-1.06%)

11:20
10/20/17
10/20
11:20
10/20/17
11:20
Options
Defensive option play opened in Sprint »

Defensive option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 16

    May

11:20
10/20/17
10/20
11:20
10/20/17
11:20
General news
Treasury Action: 3-year note is special in repo and fails rose to record highs »

Treasury Action: 3-year…

HNHPF

Hon Hai Precision

$7.28

-0.21 (-2.80%)

, AAPL

Apple

$155.98

-3.78 (-2.37%)

11:19
10/20/17
10/20
11:19
10/20/17
11:19
Periodicals
Foxconn chairman, Apple CEO intend to meet in Taiwan this month, Nikkei says »

Foxconn (HNHPF) chairman…

HNHPF

Hon Hai Precision

$7.28

-0.21 (-2.80%)

AAPL

Apple

$155.98

-3.78 (-2.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

FDC

First Data

$18.96

0.505 (2.74%)

11:18
10/20/17
10/20
11:18
10/20/17
11:18
Upgrade
First Data rating change  »

Follow-up: First Data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

$NSD

NASDAQ Market Internals

11:17
10/20/17
10/20
11:17
10/20/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
10/20/17
10/20
11:16
10/20/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBDRY

Iberdrola

$31.72

0.165 (0.52%)

, SIEGY

Siemens

$69.58

-0.295 (-0.42%)

11:11
10/20/17
10/20
11:11
10/20/17
11:11
Periodicals
Iberdrola calls for change at Siemens Gamesa after profit warning, Reuters says »

Iberdrola (IBDRY) has…

IBDRY

Iberdrola

$31.72

0.165 (0.52%)

SIEGY

Siemens

$69.58

-0.295 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SE

Sea Limited

11:11
10/20/17
10/20
11:11
10/20/17
11:11
Syndicate
Breaking Syndicate news story on Sea Limited »

Sea Limited opens at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

SE

Sea Limited

11:10
10/20/17
10/20
11:10
10/20/17
11:10
Syndicate
Breaking Syndicate news story on Sea Limited »

Sea Limited indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

XLF

Financial Select Sector

$26.55

0.22 (0.84%)

11:10
10/20/17
10/20
11:10
10/20/17
11:10
Options
SPDR Financial calls outpace puts 13:1 as shares reach multi-year highs »

SPDR Financial calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REDU

RISE Education Cayman

11:03
10/20/17
10/20
11:03
10/20/17
11:03
Syndicate
Breaking Syndicate news story on RISE Education Cayman »

RISE Education Cayman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

AEG

AEGON

$5.84

-0.06 (-1.02%)

11:00
10/20/17
10/20
11:00
10/20/17
11:00
Periodicals
ASR rebuffs Aegon takeover approach, Reuters says »

Aegon had approached…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:00
10/20/17
10/20
11:00
10/20/17
11:00
Options
10K PHLX Gold and Silver Mining Index Nov 82.5 puts bought for $1.04 »

10K PHLX Gold and Silver…

11:00
10/20/17
10/20
11:00
10/20/17
11:00
General news
Euro$ interest rate futures are on the defensive again »

Euro$ interest rate…

NSC

Norfolk Southern

$132.03

1.79 (1.37%)

10:50
10/20/17
10/20
10:50
10/20/17
10:50
Options
Bullish theme in the railroad names continues »

Bullish theme in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

DHXM

DHX Media

$3.60

-0.1999 (-5.26%)

10:48
10/20/17
10/20
10:48
10/20/17
10:48
Hot Stocks
DHX Media 'not aware' of material undisclosed information related to company »

DHX Media, in response to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

SE

Sea Limited

10:46
10/20/17
10/20
10:46
10/20/17
10:46
Syndicate
Breaking Syndicate news story on Sea Limited »

Sea Limited indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

CZR

Caesars

$12.05

-0.25 (-2.03%)

10:46
10/20/17
10/20
10:46
10/20/17
10:46
Conference/Events
Caesars to host analyst and investor day »

Analyst and Investor Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 08

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.